We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

MR Imaging Safe for Patients Implanted With Autonomic Heart-Stimulation Device

By MedImaging International staff writers
Posted on 12 May 2022
Print article
Image: BarostimNEO implantable pulse generator (Photo courtesy of CVRx)
Image: BarostimNEO implantable pulse generator (Photo courtesy of CVRx)

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body’s needs for blood and oxygen. The world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure has now received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling.

CVRx (Minneapolis, MN, USA) has received US FDA approval for MR conditional labeling for its Barostim System which now includes instructions to allow for safe MRI scans of the head and lower extremities. Barostim is an implantable device that delivers electrical pulses to baroreceptors – natural sensors in the body that tell the nervous system how to regulate heart, kidney and vascular function. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. These effects reduce the heart’s workload and help it pump more efficiently, helping to improve the symptoms for patients with heart failure.

Unlike pacemakers, ICDs, and CRT devices, Barostim does not sense and respond to electrical activity. For this reason, and the presence of a magnetic switch that automatically pauses therapy during an MRI scan, Barostim requires no pre- or post- MRI scan programming (newest models only). All Barostim System patients, including those already receiving Barostim therapy, can safely receive an MRI at 1.5T when conditions of use are met.

"This is a significant milestone for CVRx, and more importantly, for the heart failure patients benefitting from our therapy," said Nadim Yared, President and CEO of CVRx. "These heart failure patients undergo many physical assessments. This approval expands the diagnostic imaging options available to physicians for these patients, should the need arise."

Related Links:
CVRx 


Print article
CIRS -  MIRION
Radcal

Channels

Radiography

view channel
Image: Spinal fractures in the elderly are preventable with simple X-rays (Photo courtesy of Pexels)

Simple X-Ray Method Can Diagnose Vertebral Compression and Prevent Spinal Fractures

Vertebral compression means that the spine is compressed, causing a fracture in one of the vertebrae. Vertebral compression fractures (VCFs) occur easily in people with osteoporosis and are very common... Read more

Imaging IT

view channel
Illustration

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more

Industry News

view channel
Image: RSNA`s annual meeting is the world`s largest medical imaging conference (Photo courtesy of RSNA)

RSNA 2022 Sees Rise in Abstract Submissions Ahead of Annual Meeting

The Radiological Society of North America (RSNA, Oak Brook, IL, USA) has announced that nearly 10,400 scientific and educational abstracts have been submitted for the Society's 108th Scientific Assembly... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.